Luo Ying's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed May 7, 2026
- Accession no.
- 0001140361-26-019658
- Filed
- May 7, 2026
- Trade date
- May 5-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $82.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luo YingCIK 0001959160 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Common Stock | SSaleDisposed | −179 | $8.01 | −$1,433.79 | 2,575,362 | Indirect | |
| May 6, 2026 | Common Stock | SSaleDisposed | −10,136 | $8.04 | −$81,493.44 | 2,565,226 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.